...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: https://scr.zacks.co...

Thanks for that info Bear!

Interesting not to see any name attached to this piece by Zacks. Given some of the wording and information in it, it is a real stretch to believe that this was not written without any assistance from the company. Also, if the piece was paid for, and if the Jane King interview with Don in early April was paid for, how can one argue that the attendance at conferences were possibly pulled because we were in a sensitive period.

Possibly (or did they for sure?) pulling coverage of a publicly traded company and trading that for coverage of a private company that refuses to be listed?

Something isn't adding up, or is mine the minority position here?

The once promised "more frequent updates" webcasts have become such a rarity again, and the very least that the two companies could do is provide an update (webcast) now, or at least give us a broad hint of them coming within the next few weeks.

And yes, given the drought newswise and the $0.80 close on Resverlogix today, I'll even settle for ten minute webcasts at this point in time!

 

Share
New Message
Please login to post a reply